OncoMatch/Clinical Trials/NCT06778408
Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial
Is NCT06778408 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for palliative radiotherapy.
This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART. PRO-CTCAE GI scores observed in the study patients will be compared to historical rates. Secondary outcomes include measuring changes in health-related quality of life, esophageal quality of life, toxicity, dosimetric outcomes, and pain.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: cytotoxic chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Vermont Medical Center · Burlington, Vermont
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06778408 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic chemotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify